Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Other Non-Current Assets (2016 - 2026)

Protara Therapeutics' Other Non-Current Assets history spans 13 years, with the latest figure at $6.0 million for Q1 2026.

  • Quarterly Other Non-Current Assets rose 702.68% to $6.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Mar 2026, up 702.68% year-over-year, with the annual reading at $20000.0 for FY2025, 99.39% down from the prior year.
  • Other Non-Current Assets came in at $6.0 million for Q1 2026, up from $20000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $6.0 million in Q1 2026 to a low of $20000.0 in Q4 2025.
  • The 5-year median for Other Non-Current Assets is $745000.0 (2022), against an average of $1.1 million.
  • Year-over-year, Other Non-Current Assets skyrocketed 1474.0% in 2022 and then tumbled 99.39% in 2025.
  • Protara Therapeutics' Other Non-Current Assets stood at $644000.0 in 2022, then increased by 15.68% to $745000.0 in 2023, then soared by 339.19% to $3.3 million in 2024, then crashed by 99.39% to $20000.0 in 2025, then skyrocketed by 29800.0% to $6.0 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Other Non-Current Assets are $6.0 million (Q1 2026), $20000.0 (Q4 2025), and $21000.0 (Q3 2025).